# US 7,410,950 B2 · Peptides of CaV2.2 that inhibit pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,410,950 B2
- Document ID: US7410950B2
- Status: Granted
- Kind: B2
- Application number: 11/096,281
- Filed: 2005-03-31
- Published: 2005-12-01
- Granted: 2008-08-12
- Earliest claimed: 2004-04-01
- Assignees: Board of Regents, The University of Texas System
- Inventors: Mary Garry; Ilya Bezprozvanny
- Web page: https://patentgrep.com/patent/US7410950B2

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/1021: {with the first amino acid being acidic}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use of this peptide to treat pain and to use of this peptide in binding reaction with int-PDZ to screen for small molecules that can inhibit pain.

## Claims

### Claim 1

An isolated and purified peptide of 4 to 12 residues comprising the sequence DHWC (SEQ ID NO:1).

### Claim 2

A method of treating pain in an animal comprising administering to said animal a peptide of 4 to 12 residues comprising the sequence DHWC (SEQ ID NO:I) said peptide dispersed in a pharmaceutically acceptable buffer, diluent or excipient.

### Claim 3 (depends on 2)

The method of claim 2, wherein said peptide is 12 residues in length.

### Claim 4 (depends on 2)

The method of claim 2, wherein said peptide is 8 residues in length.

### Claim 5 (depends on 2)

The method of claim 2, wherein said peptide is 4 residues in length.

### Claim 6 (depends on 2)

The method of claim 2, wherein said peptide is further comprised within a lipid vehicle.

### Claim 7 (depends on 6)

The method of claim 6, wherein said lipid vehicle is a liposome.

### Claim 8 (depends on 2)

The method of claim 2, wherein the pain to be treated is selected from the group consisting of neuropathic pain, inflammatory pain and pain secondary to cancer.

### Claim 9 (depends on 2)

The method of claim 2, further comprising administering a second anti-pain agent to said animal.

### Claim 10 (depends on 2)

The method of claim 2, wherein said second anti-pain agent is a steroid, an NSAID, or an opioid.

### Claim 11 (depends on 2)

The method of claim 2, wherein said animal is a human.

### Claim 12 (depends on 2)

The method of claim 2, wherein said animal is a dog, a cat, a rat, a mouse, a horse, a cow or a rabbit.